Press Releases Silence Therapeutics plc OTC Markets

Equities

SLNCF

GB00B9GTXM62

Market Closed - OTC Markets Other stock markets 13:56:14 2024-07-02 EDT			5-day change	1st Jan Change
6 ^USD	-7.69%		-7.69%	+300.00%

07-02	European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	MT
06-28	European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients	06-27	BU
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration	06-24	BU
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)	06-20	BU
Silence Therapeutics to Present at Jefferies Global Healthcare Conference	05-30	BU
Silence Therapeutics : Condensed consolidated income statement (unaudited) - Form 6-K	05-16	PU
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress	05-16	BU
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference	04-30	BU
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors	04-29	BU
Silence Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION - Form 6-K	04-15	PU
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)	04-08	BU
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights	03-13	BU
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)	03-13	BU
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024	02-28	BU
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial	02-26	AQ
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial	02-23	BU
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement	02-05	BU
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	01-31	BU
Gubra concludes the research agreement with UK Biotech	01-26	AQ
Silence Therapeutics : Curtis Rambaran, MD, promoted to Chief Medical Officer Marie Wikström Lindholm, PhD, promoted to Chief Scientific Officer - Form 6-K	12-01	PU
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments	12-01	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Silence Therapeutics plc OTC Markets

Equities

SLNCF

GB00B9GTXM62

Press Releases

Filters